Timothy Waterhouse
Timothy Waterhouse
Metrum Research Group
Verified email at metrumrg.com
Title
Cited by
Cited by
Year
Some considerations on the design of population pharmacokinetic studies
S Duffull, T Waterhouse, J Eccleston
Journal of pharmacokinetics and pharmacodynamics 32 (3), 441-457, 2005
752005
Evaluation of Various Static In VitroIn Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
MLT Vieira, B Kirby, I Ragueneau‐Majlessi, A Galetin, JYL Chien, ...
Clinical Pharmacology & Therapeutics 95 (2), 189-198, 2014
702014
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients
TH Waterhouse, S Redmann, SB Duffull, JA Eccleston
Journal of Pharmacokinetics and Pharmacodynamics 32 (3-4), 521-545, 2005
582005
A d‐optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients
S Hennig, TH Waterhouse, SC Bell, M France, CE Wainwright, H Miller, ...
British journal of clinical pharmacology 63 (4), 438-450, 2007
462007
Design selection criteria for discrimination/estimation for nested models and a binomial response
TH Waterhouse, DC Woods, JA Eccleston, SM Lewis
Journal of statistical planning and inference 138 (1), 132-144, 2008
352008
Optimal design criteria for discrimination and estimation in nonlinear models
TH Waterhouse, JA Eccleston, SB Duffull
Journal of biopharmaceutical statistics 19 (2), 386-402, 2009
272009
Optimal experimental design for nonlinear and generalised linear models
TH Waterhouse
222005
The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins
S Friedrich, JJP Kastelein, D James, T Waterhouse, SE Nissen, ...
CPT: pharmacometrics & systems pharmacology 3 (1), 1-9, 2014
162014
On optimal design for discrimination and estimation
TH Waterhouse, JA Eccleston, SB Duffull
COMPSTAT 2004: Proceedings in Computational Statistics, 1963-1970, 2004
152004
Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease
EB Wang, A Chaudhary, TH Waterhouse, GL Dickinson
The Journal of Clinical Pharmacology 57 (6), 739-746, 2017
112017
Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients
V Krishnan, NJ Patel, JG Mackrell, SA Sweetana, H Bullock, YL Ma, ...
Andrology 6 (3), 455-464, 2018
102018
Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
I Gueorguieva, J Tabernero, D Melisi, T Macarulla, V Merz, ...
Cancer chemotherapy and pharmacology 84 (5), 1003-1015, 2019
92019
Optimal crossover designs for logistic regression models in pharmacodynamics
TH Waterhouse, JA Eccleston, SB Duffull
Journal of biopharmaceutical statistics 16 (6), 881-894, 2006
92006
Designs for generalized linear models with random block effects
TW Waite, DC Woods, TH Waterhouse
Southampton, GB, Southampton Statistical Sciences Research Institute, 23pp …, 2012
62012
Design selection criteria for discrimination between nested models for binomial data
TH Waterhouse, DC Woods, JA Eccleston, SM Lewis
Southampton Statistical Sciences Research Institute, 2006
32006
Exposure-response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+ gemcitabine (GG) or gemcitabine+ placebo (GP …
I Gueorguieva, J Tabernero, D Melisi, TH Waterhouse, C Miles, ...
Cancer Research 76 (14 Supplement), 2046-2046, 2016
22016
A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis
S Hennig, TH Waterhouse, CE Wainwright, SC Bell, H Miller, BG Charles, ...
Age (y) 26, 16-61, 2006
12006
Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes
X Ma, T Waterhouse, LL Ilag, T Ly, R Juneja, P Garhyan, T Hardy, ...
Journal of Diabetes Science and Technology 15 (5), 1195-1197, 2021
2021
An Approach to Incorporating Variability into a Quantitative Systems Pharmacology Model for Diabetes
TH Waterhouse, JK Leohr, JS Geiser, MA Heathman
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S116-S116, 2017
2017
Impact of Model Uncertainty on Phase 2 Diabetes Trial Design
TH Waterhouse, X Ma, JY Chien
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S85-S86, 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20